These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 32894020)
1. Discovery and Optimization of Small-Molecule Ligands for V-Domain Ig Suppressor of T-Cell Activation (VISTA). Gabr MT; Gambhir SS J Am Chem Soc; 2020 Sep; 142(38):16194-16198. PubMed ID: 32894020 [TBL] [Abstract][Full Text] [Related]
2. Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA. Li TT; Jiang JW; Qie CX; Xuan CX; Hu XL; Liu WM; Chen WT; Liu J BMC Immunol; 2021 Aug; 22(1):55. PubMed ID: 34380434 [TBL] [Abstract][Full Text] [Related]
3. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. Wang L; Rubinstein R; Lines JL; Wasiuk A; Ahonen C; Guo Y; Lu LF; Gondek D; Wang Y; Fava RA; Fiser A; Almo S; Noelle RJ J Exp Med; 2011 Mar; 208(3):577-92. PubMed ID: 21383057 [TBL] [Abstract][Full Text] [Related]
4. VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance. Schaafsma E; Croteau W; ElTanbouly M; Nowak EC; Smits NC; Deng J; Sarde A; Webber CA; Rabadi D; Cheng C; Noelle R; Lines JL Cancer Immunol Res; 2023 Jan; 11(1):38-55. PubMed ID: 36260656 [TBL] [Abstract][Full Text] [Related]
5. High-Affinity Anti-VISTA Antibody Protects against Sepsis by Inhibition of T Lymphocyte Apoptosis and Suppression of the Inflammatory Response. Tao T; Bo L; Li T; Shi L; Zhang H; Ye B; Xu Y; Ma Q; Deng X; Zhang G Mediators Inflamm; 2021; 2021():6650329. PubMed ID: 34366711 [TBL] [Abstract][Full Text] [Related]
6. VISTA is an immune checkpoint molecule for human T cells. Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993 [TBL] [Abstract][Full Text] [Related]
7. Structural Basis of VSIG3: The Ligand for VISTA. Xie X; Chen C; Chen W; Jiang J; Wang L; Li T; Sun H; Liu J Front Immunol; 2021; 12():625808. PubMed ID: 33841409 [TBL] [Abstract][Full Text] [Related]
8. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B Front Immunol; 2021; 12():676181. PubMed ID: 34093577 [TBL] [Abstract][Full Text] [Related]
9. Novel Benzimidazoles as Potent Small-Molecule Inhibitors and Degraders of V-Domain Ig Suppressor of T-Cell Activation (VISTA). Wang T; Wang K; Zhang Y; Zhang K; Cai S; Jiang S; Xiao Y; Zhang X J Med Chem; 2023 Sep; 66(17):11881-11892. PubMed ID: 37594853 [TBL] [Abstract][Full Text] [Related]
10. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy. Yuan L; Tatineni J; Mahoney KM; Freeman GJ Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077 [TBL] [Abstract][Full Text] [Related]
11. VISTA: A promising target for overcoming immune evasion in gynecologic cancers. Liu S; Ji F; Ding Y; Ding B; Feng S; Brennick C; Lin H; Zhang T; Shen Y Int Immunopharmacol; 2024 Sep; 138():112655. PubMed ID: 38986302 [TBL] [Abstract][Full Text] [Related]
12. Small molecules from antibody pharmacophores (SMAbPs) as a hit identification workflow for immune checkpoints. Abdel-Rahman SA; Gabr MT Sci Adv; 2024 Oct; 10(42):eadq5540. PubMed ID: 39413175 [TBL] [Abstract][Full Text] [Related]
13. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845 [TBL] [Abstract][Full Text] [Related]
14. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. Huang X; Zhang X; Li E; Zhang G; Wang X; Tang T; Bai X; Liang T J Hematol Oncol; 2020 Jun; 13(1):83. PubMed ID: 32600443 [TBL] [Abstract][Full Text] [Related]
15. The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers. Wang G; Tai R; Wu Y; Yang S; Wang J; Yu X; Lei L; Shan Z; Li N Cytokine Growth Factor Rev; 2020 Apr; 52():1-14. PubMed ID: 32057701 [TBL] [Abstract][Full Text] [Related]
16. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA. Mehta N; Maddineni S; Kelly RL; Lee RB; Hunter SA; Silberstein JL; Parra Sperberg RA; Miller CL; Rabe A; Labanieh L; Cochran JR Sci Rep; 2020 Sep; 10(1):15171. PubMed ID: 32938950 [TBL] [Abstract][Full Text] [Related]
17. VSIG-3 as a ligand of VISTA inhibits human T-cell function. Wang J; Wu G; Manick B; Hernandez V; Renelt M; Erickson C; Guan J; Singh R; Rollins S; Solorz A; Bi M; Li J; Grabowski D; Dirkx J; Tracy C; Stuart T; Ellinghuysen C; Desmond D; Foster C; Kalabokis V Immunology; 2019 Jan; 156(1):74-85. PubMed ID: 30220083 [TBL] [Abstract][Full Text] [Related]
18. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Deng J; Li J; Sarde A; Lines JL; Lee YC; Qian DC; Pechenick DA; Manivanh R; Le Mercier I; Lowrey CH; Varn FS; Cheng C; Leib DA; Noelle RJ; Mabaera R Cancer Immunol Res; 2019 Jul; 7(7):1079-1090. PubMed ID: 31088847 [TBL] [Abstract][Full Text] [Related]
19. VISTA expressed in tumour cells regulates T cell function. Mulati K; Hamanishi J; Matsumura N; Chamoto K; Mise N; Abiko K; Baba T; Yamaguchi K; Horikawa N; Murakami R; Taki M; Budiman K; Zeng X; Hosoe Y; Azuma M; Konishi I; Mandai M Br J Cancer; 2019 Jan; 120(1):115-127. PubMed ID: 30382166 [TBL] [Abstract][Full Text] [Related]
20. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated. Mortezaee K; Majidpoor J; Najafi S Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]